Latest Alcohols Stories

Ranbaxy to Market Desvenlafaxine Base Extended Release Tablets in the U.S.

2013-03-05 12:28:51

Enters into an in-licensing business agreement with Alembic PRINCETON, N.J., March 5, 2013 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it has entered into an in-licensing agreement with Alembic Pharmaceuticals Limited to exclusively market Desvenlafaxine Base Extended Release Tablets in the U.S. healthcare system. Alembic Pharmaceuticals Limited is the sponsor and manufacturer of the New...

Relmada Therapeutics Announces LevoCap ER Development Progress

2013-03-04 12:28:46

Relmada Therapeutics announces the approval of its CTA (Clinical Trial Authorization) by the MHRA (Medicines and Healthcare products Regulatory Agency) in the United Kingdom to conduct a Phase 1 pharmacokinetic study with LevoCap ER. BLUE BELL, Pa., March 4, 2013 /PRNewswire/ -- Relmada Therapeutics, Inc., a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced the approval of the application of a Clinical Trial Authorization (CTA) that...

Cardiome announces settlement of debt and termination of line of credit with Merck

2013-03-04 08:29:26

VANCOUVER, March 4, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced it has made the final payment to Merck, known as MSD outside the United States and Canada, of $13 million (currency in U.S. dollars) which has been accepted by Merck as full and final settlement of all amounts owing under the line of credit stemming from the companies' collaboration and license agreement for vernakalant, signed in April 2009. Under the terms of the December 10,...

BioDelivery Sciences to Present at the Cowen and Company 33rd Annual Health Care Conference

2013-03-01 08:24:58

RALEIGH, N.C., March 1, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the Cowen and Company 33(rd) Annual Health Care Conference. The presentation is scheduled for Tuesday, March 5, 2013 at 10:40 a.m. Eastern Time, at The Boston Marriott Copley Place. (Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO ) Dr. Sirgo will focus on the development...

Longer Days Aren’t the Only Way Canadians Can Beat the Winter Blues

2013-02-28 23:02:53

As the days grow longer, Canadians suffering from Seasonal Affective Disorder (S.A.D.) are starting to feel a bit better. New research into the use of vitamin D in the treatment of S.A.D. gives hope to the sufferers who cannot find relief from the traditional light therapy. That’s good news for Life Science Nutritionals, the makers of Adult Essentials Vitamin D gummies. Burlington, Ontario (PRWEB) February 28, 2013 As the days grow longer, Canadians suffering from Seasonal Affective...

QRxPharma Resubmits MOXDUO® New Drug Application to the FDA

2013-02-28 08:31:04

Successful NDA Review to Position Product for Approval in Q3 2013 SYDNEY and BEDMINSTER, N.J., Feb. 28, 2013 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today that the Company resubmitted its MOXDUO(® )New Drug Application (NDA). As disclosed on 16 January 2013, at its last meeting with the Company, the US Food and Drug Administration (FDA) requested the resubmission of the NDA to include the respiratory safety results of Study 022. "We believe the...

Collegium Pharmaceutical's CEO to Present at the Cowen & Company 33rd Annual Health Care Conference in Boston on March 6, 2013

2013-02-28 08:29:03

CANTON, Mass., Feb. 28, 2013 /PRNewswire/ -- Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced that the company's President and CEO, Michael Heffernan, will present the company's corporate overview on Wednesday, March 6, 2013 at 11:00 am EST at the Cowen & Company 33(rd) Annual Health Care Conference. The conference will be held at the Boston Marriott Copley Place in Boston, Massachusetts. The Company's lead development program is Oxycodone...

Former March of Dimes Medical Director Honored for Work to Prevent Birth Defects

2013-02-27 12:27:43

Dr. Richard Johnston Receives Award for Work to Fortify Grain Supply with Folic Acid ATLANTA, Feb. 27, 2013 /PRNewswire-USNewswire/ -- A former March of Dimes medical director who pushed for federally mandated folic acid fortification and led a public education campaign on the benefits of the B vitamin in preventing serious birth defects of the brain and spine will receive the Godfrey Oakley award for his achievements. (Logo: http://photos.prnewswire.com/prnh/20130214/DC59689LOGO)...

BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event

2013-02-27 08:28:09

RALEIGH, N.C., Feb. 27, 2013 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today announced that the Company will host "Treatment of Pain and Opioid Dependence with Buprenorphine" for investors and analysts on Thursday, March 7, 2013 at 12:00 pm, in New York City. This event will include insightful discussion from medical experts with extensive experience in the management of chronic pain and opioid dependence using various formulations of buprenorphine,...

AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation

2013-02-26 08:28:13

SAN FRANCISCO, Feb. 26, 2013 /PRNewswire/ -- AstraZeneca today announced high-level results from KODIAC-08, an open-label, randomised, 52-week, long-term safety trial of naloxegol versus usual care (UC) in patients with non-cancer related pain and opioid-induced constipation (OIC). UC was defined as the investigator's choice of an existing laxative treatment regimen for OIC. This is the fourth trial in the naloxegol Phase III development programme, and was designed to evaluate the...